Veröffentlichungen

Publikationen

• Menz W., Pathophysiologie und Behandlung kardiovaskulärer Erkrankungen. 2. Koronare Herzkrankheit. PZ Prisma 1997, 4: 5-12;
• Litzinger A. und Schweitzer E., Neue Wege einer intensivierten pharmazeutischen Betreuung. Krankenhauspharmazie 1998, 1: 9-13;
• Menz W., AT1-Rezeptorantagonisten, Vergleichende Darstellung einer neuen Arzneimittelklasse zur Therapie des Bluthochdrucks - Teil 1. PZ Prisma 1999, 6: 35-41;
• Menz W., AT1-Rezeptorantagonisten, Vergleichende Darstellung einer neuen Arzneimittelklasse zur Therapie des Bluthochdrucks - Teil 2. PZ Prisma 1999, 6: 90-96;
• Holzschuh G., Litzinger A. und Schweitzer E., Arzneimittelvorrat auf Station ist Sache der Apotheke. Die Schwester Der Pfleger 1999, 6: 472-475;
• •Menz W., ACE-Hemmer in der Kitteltasche. Krankenhauspharmazie 2000, 8: 427-431;
• Menz W. und Schweitzer E., Glykoprotein-IIb/IIIa-Rezeptorantagonisten bei akutem Koronarsyndrom. Teil 1: Grundlagen; Krankenhauspharmazie 2003, 6: 226-231;
• Menz W. und Schweitzer E., Glykoprotein-IIb/IIIa-Rezeptorantagonisten bei akutem Koronarsyndrom. Teil 2: Klinische Studien mit Tirofiban und Eptifibatid; Krankenhauspharmazie 2003, 9: 357-366;
• Menz W. und Schweitzer E., Glykoprotein-IIb/IIIa-Rezeptorantagonisten bei akutem Koronarsyndrom. Teil 3: Klinische Studien mit Abciximab; Krankenhauspharmazie 2003, 10: 411-424;
• Menz W., AABG: Preisgünstige Therapiealternativen nach § 115c SGB V, ACE-Hemmstoffe. Krankenhauspharmazie 2003, 11: 462-469;
• Menz W., ACE-Hemmstoffe, AABG: Preisgünstige Therapiealternativen nach § 115c SGB V. Arzneimitteltherapie 2005, 23: 157-164;
• Menz, W., AABG: Preisgünstige Therapiealternativen nach § 115c SGB V, Insuline. Krankenhauspharmazie 2006, 27: 93-102;
• Litzinger A. und Schweitzer E., 10 Jahre Mannheimer Modell im Theresienkrankenhaus. Krankenhauspharmazie 2006, 27: 267-270;
• Menz, W., Insuline, Ein Vergleich der handelsüblichen Präparate. Medizinische Monatsschrift für Pharmazeuten 2006, 29: 97-100;
• Menz, W., Insuline, AABG: Preisgünstige Therapiealternativen nach § 115c SGB V. Arzneimitteltherapie 2006, 24: 187-196;
• Menz W., Die Beurteilung der Nierenfunktion bei Erwachsenen. PZ Prisma 2008, 1: 13-20;
• Menz W: Insulin. In: Krämer I, Jelkmann W: Rekombinante Arzneimittel - Medizinischer Fortschritt durch Biotechnologie, 2. Auflage, Springer Verlag Berlin Heidelberg 2011, S.61-71.
• Menz W., Aktuelle Marktübersicht der Insulinzubereitungen in Deutschland. Krankenhauspharmazie 2014, 10: 371-375.

Posterpräsentationen

• Litzinger A., Schweitzer E., Mildenberger S., Niedermolekulare Heparine in Multidose-Injektionsflaschen: Was bringt die Umstellung? Vorgestellt beim 28. wissenschaftlichen Kongress der ADKA e.V. in Köln 2000;
• Schweitzer E., Litzinger A., Ellmann T., Bauer G., Management von Notfallarzneimitteln am Beispiel von Präparaten zur HIV-Prophylaxe. Vorgestellt bei der 8. Fachtagung der ADKA e.V. in Mannheim 2001;
• Litzinger A. und Schweitzer E., Ellmann B., Erfassung und Dokumentation resistenter Keime nach Infektionsschutzgesetz. Klinisch-mikrobiologische Serviceleistungen der Krankenhausapotheke. Vorgestellt bei der 8. Fachtagung der ADKA e.V. in Mannheim 2001;
• Reich C.D., Schweitzer E., Pharmazeutische Interventionen bei Patienten mit Niereninsuffizienz auf der Gefäßchirurgie. Vorgestellt beim 32. wissenschaftlichen Kongress der ADKA e.V. in Weimar 2007;
• Klump B., Reich C.D., Menz W., Schweitzer E., Projekt "Zentrale Arzneimittelaufnahme" (Februar - Dezember 2009). Vorgestellt beim 35. wissenschaftlichen Kongress der ADKA e.V. in Freiburg 2010.

• Spezielle gastroenterologische Onkologie im Alter. Rudi J. In: Geriatrische Gastroenterologie Mayet W-J (Hrsg.) 2022; 252-285 Walter de Gruyter Berlin / Boston
• Geriatrische gastrointestinale Onkologie: Ösophagus, Magen, Dickdarm. Rudi J. in Gastroenterologe 2021;16:369-377
• Percutaneous transhepatic or endoscopic ultrasound-guided biliary drainage in malignant distal bile duct obstruction using a self-expanding metal stent: Study protocol for a prospective European multicenter trial (PUMa trial). Schmitz D, Valiente CT, Dollhopf M, Perez-Miranda M, Küllmer A, Gornals J, Vila J, Weigt J, Voigtländer T, Redondo-Cerezo E, von Hahn T, Albert J, Vom Dahl S, Beyna T, Hartmann D, Franck F, García-Alonso FJ, Schmidt A, Garcia-Sumalla A, Arrubla A, Joerdens M, Kleemann T, Tomo JRA, Grassmann F, Rudi J. PLoS One. 2022 Oct 27;17(10):e0275029.
• KRAS/GNAS-testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas. Schmitz D, Kazdal D, Allgäuer M, Trunk M, Vornhusen S, Nahm AM, Doll M, Weingärtner S, Endris V, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Budczies J, Kienle P, Magdeburg R, Hetjens S, Schirmacher P, Bergmann F, Rudi J, Stenzinger A, Volckmar AL.Genes Chromosomes Cancer. 2021 Jul;60(7):489-497.
• Hemosuccus pancreaticus due to a small arterial pseudoaneurysm detected by CE-EUS and successfully treated with angiographic coiling (with video). Schmitz D, Hansmann J, Rudi J. Endosc Ultrasound. 2021 Nov-Dec;10(6):476-478.
• Gallbladder Cancer Presenting as Mirizzi Syndrome Complicated by Rapidly Evolving 23 rRNA Gene-Linezolid Resistance with Vancomycin-Resistant Enterococcus Infection Resulting in Fatal Cholangial Sepsis. Schmitz D, Eigner U, Schmidt-Wieland T, Weber P, Magdeburg R, Kienle P, Rudi J. Case Rep Gastroenterol. 2020 Oct 28;14(3):540-546.
• Preventive Transhepatic Tract Embolisation after Percutaneous Biliary Interventions: A Systematic Review. Schmitz D, Chang DH, Rudi J, Hetjens S, Ebert MPA. Can J Gastroenterol Hepatol. 2020 Oct 1;2020:8849284.
• Is insertion of a plastic stent better and safer than epinephrine injection in post sphincterotomy bleeding? Schmitz D, Weller N, Doll M, Werle S, Mees C, Prinz P, John B, Schmidt D, Günther A, Weiß C, Rudi J. Eur J Gastroenterol Hepatol. 2020 Apr;32(4):484-489.
• Patient radiation dose in percutaneous biliary interventions: recommendations for DRLs on the basis of a multicentre study. Schmitz D, Vogl T, Nour-Eldin NA, Radeleff B, Kröger JC, Mahnken AH, Ittrich H, Gehl HB, Plessow B, Böttcher J, Tacke J, Wispler M, Rosien U, Schorr W, Joerdens M, Glaser N, Fuchs ES, Tal A, Friesenhahn-Ochs B, Leimbach T, Höpner L, Weber M, Gölder S, Böhmig M, Hetjens S, Rudi J, Schegerer A. Eur Radiol. 2019 Jul;29(7):3390-3400.
• Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Volckmar AL, Endris V, Gaida MM, Leichsenring J, Stögbauer F, Allgäuer M, von Winterfeld M, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Schirmacher P, Rudi J, Schmitz D, Stenzinger A. Genes Chromosomes Cancer. 2019 Jan;58(1):3-11.
• Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. Schimanski CC, Staib F, Göhler T, Hebart H, Heike M, Neise M, Rudi J, Geer T, Dingeldein G, Lang C, Ehscheidt P, Flohr T, Josten KM, Karthaus M, Schmittel A, Wierecky J, Boller E, Indorf M, Wörns MA, Galle PR, Moehler M. J Cancer Res Clin Oncol. 2017 Jun;143(6):1023-1034.
• Color Doppler ultrasound-guided PTBD with and without metal stent implantation by endoscopic control: prospective success and early adverse event rates. Schmitz D, Grosse A, Hallscheidt P, Roseneck A, Niemeyer J, Rudi J. Z Gastroenterol. 2015 Nov;53(11):1255-60.
• Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Ann Oncol. 2013 Sep;24(9):2342-9.
• Helicobacter pylori-induced apoptosis in T cells is mediated by the mitochondrial pathway independent of death receptors. Ganten TM, Aravena E, Sykora J, Koschny R, Mohr J, Rudi J, Stremmel W, Walczak H. Eur J Clin Invest. 2007 Feb;37(2):117-25.
• Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Neuhof D, Neumayer F, Einbeck W, Haschemian K, Mai SK, Hochhaus A, Willeke F, Rudi J, Debus J, Wenz F. Acta Oncol. 2005;44(2):168-73.
• Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer. Rudi J, Werle S, Bergtholdt D, Hofheinz RD. Onkologie. 2005 Mar;28(3):128-32.
• Detection of disseminated tumour cells as a potential surrogate-marker for monitoring palliative chemotherapy in colorectal cancer patients. Staritz P, Kienle P, Koch M, Benner A, von Knebel Doeberitz M, Rudi J, Weitz J. J Exp Clin Cancer Res. 2004 Dec;23(4):633-9.
• Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Rühl A, Irngartinger G, Stremmel W, Rudi J. J Nucl Med. 2004 Sep;45(9):1480-7.
• Role of apoptosis and CD95-receptor/ligand system in aspirin- and Helicobacter pylori-induced cell death. Domhan S, Stremmel W, Rudi J.Eur J Clin Invest. 2004 Jun;34(6):422-8.
• Association between cerebral ischemia and cytotoxin-associated gene-A-bearing strains of Helicobacter pylori. Preusch MR, Grau AJ, Buggle F, Lichy C, Bartel J, Black C, Rudi J. Stroke. 2004 Aug;35(8):1800-4.
• Salt and stomach cancer: chances for healthy nutrition. Stomach cancer--what is really reliable? Rudi J. Krankenpfl J. 2003;41(10-12):220-1.
• PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Dimitrakopoulou-Strauss A, Strauss LG, Rudi J. Q J Nucl Med. 2003 Mar;47(1):8-13.
• Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. Moehler M, Gutzler F, Steinmann S, Boehme M, Raeth U, Stremmel W, Galle PR, Rudi J. Chemotherapy. 2003 May;49(1-2):85-9. doi: 10.1159/000069778.
• Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. Grau AJ, Buggle F, Lichy C, Brandt T, Becher H, Rudi J. J Neurol Sci. 2001 May 1;186(1-2):1-5.
• Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma. Teufel A, Lehnert T, Stremmel W, Rudi J. Z Gastroenterol. 2000 Nov;38(11):909-12.
• Helicobacter pylori vacA genotypes and cagA gene in a series of 383 H. pylori-positive patients. Rudi J, Kuck D, Rudy A, Sieg A, Maiwald M, Stremmel W. Z Gastroenterol. 2000 Jul;38(7):559-64.
• Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas. Wagner V, Rudi J, Näher H, Stremmel W. Med Oncol. 2000 Feb;17(1):35-8.
• Role of apoptosis in gastric epithelial turnover. von Herbay A, Rudi J. Microsc Res Tech. 2000 Mar 1;48(5):303-11.
• Therapy of pseudomyxoma peritonei of appendiceal origin--surgical resection and intraperitoneal chemotherapy. Hosch WP, Rudi J, Stremmel W. Z Gastroenterol. 1999 Jul;37(7):615-22.
• Direct determination of Helicobacter pylori vacA genotypes and cagA gene in gastric biopsies and relationship to gastrointestinal diseases. Rudi J, Rudy A, Maiwald M, Kuck D, Sieg A, Stremmel W. Am J Gastroenterol. 1999 Jun;94(6):1525-31.
• Helicobacter sp. are not detectable in bile from German patients with biliary disease. Rudi J, Rudy A, Maiwald M, Stremmel W. Gastroenterology. 1999 Apr;116(4):1016-7.
• Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. Rudi J, Kuck D, Strand S, von Herbay A, Mariani SM, Krammer PH, Galle PR, Stremmel W. J Clin Invest. 1998 Oct 15;102(8):1506-14.
• Diversity of Helicobacter pylori vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases. Rudi J, Kolb C, Maiwald M, Kuck D, Sieg A, Galle PR, Stremmel W. J Clin Microbiol. 1998 Apr;36(4):944-8.
• Esophageal ulcer with heterotopy of the gastric mucosa and fistula. Rudi J, Stremmel W. Dtsch Med Wochenschr. 1998 Feb 27;123(9):269.
• Prevalence of serum antibodies to Helicobacter pylori and to CagA protein in liver transplant recipients. Rudi J, Engler S, Theilmann L, Otto G, Stremmel W. Am J Gastroenterol. 1997 Sep;92(9):1492-5.
• Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. Rudi J, Kolb C, Maiwald M, Zuna I, von Herbay A, Galle PR, Stremmel W. Dig Dis Sci. 1997 Aug;42(8):1652-9.
• Risk of infection with Helicobacter pylori and hepatitis A virus in different groups of hospital workers. Rudi J, Töppe H, Marx N, Zuna I, Theilmann L, Stremmel W, Raedsch R. Am J Gastroenterol. 1997 Feb;92(2):258-62.
• Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Gugler R, Hartmann M, Rudi J, Brod I, Huber R, Steinijans VW, Bliesath H, Wurst W, Klotz U. Br J Clin Pharmacol. 1996 Aug;42(2):249-52.
• Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy. Rudi J, Schönig T, Stremmel W. Z Gastroenterol. 1996 Mar;34(3):188-91.
• Serum hepatocyte growth factor levels in primary biliary cirrhosis. Rudi J, Waldherr R, Raedsch R, Stremmel W. Eur J Gastroenterol Hepatol. 1995 Nov;7(11):1081-6.
• Lack of association of Helicobacter pylori seroprevalence and gastric cancer in a population with low gastric cancer incidence. Rudi J, Müller M, von Herbay A, Zuna I, Raedsch R, Stremmel W, Räth U. Scand J Gastroenterol. 1995 Oct;30(10):958-63.
• Development of malignancies and chronic inflammations of the gastrointestinal tract--new concepts. Rudi J. Leber Magen Darm. 1995 Jul;25(4):184-5.
• Effect of ursodeoxycholic acid on biochemical parameters, hepatocyte proliferation and liver histology in galactosamine hepatitis in the rat. Rudi J, Schlenker T, Raedsch R, Waldherr R, Zorn M, Stremmel W. Res Exp Med (Berl). 1995;195(5):309-15.
• Simultaneous gastric adenocarcinoma and MALT-type lymphoma in Helicobacter pylori infection. von Herbay A, Schreiter H, Rudi J. Virchows Arch. 1995;427(4):445-50.
• Hepatocyte proliferation in primary biliary cirrhosis as assessed by proliferating cell nuclear antigen and Ki-67 antigen labelling. Rudi J, Waldherr R, Raedsch R, Kommerell B. J Hepatol. 1995 Jan;22(1):43-9.
• Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. Rudi J, Raedsch R, Gerteis C, Schlenker T, Plachky J, Walter-Sack I, Sabouraud A, Scherrmann JM, Kommerell B. Scand J Gastroenterol. 1994 Apr;29(4):346-51.
• Visceral leishmaniasis (kala-azar) after a visit to the Mediterranean region. Rudi J, Racz P, Hörner M, Kommerell B. Clin Investig. 1993 Aug;71(8):616-9.
• Lack of accumulation of midazolam in plasma and lipoprotein fractions during intravenous lipid infusions in patients on artificial respiration. Walter-Sack I, de Vries JX, Rudi J, Conradi R, Kohlmeier M, Kohl B, Weber E. Eur J Clin Pharmacol. 1992;42(1):71-5.
• The determination of total and unbound midazolam in human plasma. A comparison of high performance liquid chromatography, gas chromatography and gas chromatography/mass spectrometry. de Vries JX, Rudi J, Walter-Sack I, Conradi R. Biomed Chromatogr. 1990 Jan;4(1):28-33.
• Increased prevalance of colorectal adenoma in patients with sporadic duodenal adenoma. Dariusz A, Jochen R. Eur J Gastroenterol Hepatol. 2009 Jul;21(7):816-8.

• Liste der Veröffentlichungen von Prof. Dr. Dieter Schilling 

1. Hambsch N, Warken M, Soehendra M, Rittmann M, Wolf J. Zunehmende spastische Paraparese bei 38-jähriger Patientin aus Sierra Leone. DG Neurologie 2021; DOI 10.1007/s42451-020-00270-x

2. Wolf J. Neurologische Notfälle bei rheumatologischen Erkrankungen. Arthritis und Rheuma 2020; 40: 391-400; DOI 10.1055/a-1286-7407

3. Dorst J, Chen L, Rosenbohm A, Dreyhaupt J, Hübers A, Schuster J, Weishaupt JH, Kassubek J, Gess B, Meyer T, Weyen U, Hermann A, Winkler J, Grehl T, Hagenacker T, Lingor P, Koch JC, Sperfeld A, Petri S, Großkreutz J, Metelmann M, Wolf J, Winkler AS, Klopstock T, Boentert M, Johannesen S, Storch A, Schrank B, Zeller D, Liu XL, Tang L, Fan DS, Ludolph AC. Prognostic factors in ALS: a comparison between Germany and China. J Neurol 2019;266:1516-1525   

4. Müller K, Brenner D, Weydt P, …German ALS network MND-NET (u.a. Wolf J). Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry 2018;89:817-827   

5. Wolf J  Safer A, Maschke M, Nix WA, Wöhrle JC, Grau AJ. Epidemiologie der Amyotrophen Lateralsklerose: Daten aus dem ALS-Register Rheinland-Pfalz. Ärzteblatt Rheinland-Pfalz 2018;6:22-23  

6. Brenner D, Yilmaz R, Müller K, …German Network MND-Net (u.a. Wolf J). Hot-spot KIF5A mutations cause familial ALS. Brain 2018;141:688-697   

7. Funke A, Spittel S, Grehl T, Großkreutz J, Kettemann D, Petri S, Weyen U, Weydt P, Dorst J, Ludolph A, Baum P, Oberstadt M, Jordan B, Hermann A, Wolf J, Boentert M, Walter B, Gajewski N, Maier A, Münch C, Meyer T. Assistive technology devices in Amyotrophic Lateral Sclerosis - analysis of 4 years of platform-based case management. Amyotroph Lat Scler Frontotemp Degeneration 2018;19:342-350   

8. Van den Berg L, Van Damme P, Svenstrup K, Karlsborg M, Laaksovirta H, Salachas F, Corcia P, Couratier P, Desnuelle C, Grosskreutz J, Meyer T, Petri S, Koch JC, Weydt P, Wolf J,  Grehl T, Ludolph A, Hardiman O, Chiò A, Silani V, van der Kooi A, Holmøy T,  Kleveland G, Tysnes OB, Kuźma-Kozakiewicz M, de Carvalho M, Chandran S, Koritnik B, Mora J, Povedano M, Andersen P,  Mitre Ropero B, Nygren I, Staaf G, Ingre C, Danielsson O, Weber M, Shaw P, McDermott C, Talbot K, Al-Chalabi A. ENCALS statement on edaravone. Amyotroph Lat Scler Frontotemp Degeneration 2017;18:471-474   

9. Van Doormaal PC, Ticozzi N, Weishaupt JH, Kenna K, Diekstra FP, Verde F, Andersen PM, Dekker AM, Tiloca C, Marroquin N, Overste DJ, Pensato V, Nürnberg P, Pulit SL, Schellevis RD, Calini D, Altmüller J,  Francioli LC, Castellotti B, Motameny S, Ratti A, Wolf J, Gellera C, Ludolph AC, Van den Berg LH, Kubisch C, Landers JE, Veldink JH, Silani V, Volk AE. The role of de novo mutations in the development of amyotrophic lateral sclerosis. Human Mutation 2017:38:1534-1541   

10. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ. Todesursachen bei Amyotropher Lateralsklerose: Ergebnisse aus dem ALS-Register Rheinland-Pfalz. Nervenarzt 2017;88:911-918   

11. Wolf J, Safer A. Amyotrophe Lateralsklerose: Was die ALS-Phänotypen für die Prognose bedeuten. Neurotransmitter 2017;28:29-32   

12. Wolf J. Sein härtester Kampf. Todesursachen bei der ALS. Ärzte-Woche 2017;16:4-5   

13. Wolf J,  Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ. Factors predicting survival in ALS patients - Data from a population-based registry in Rhineland-Palatinate, Germany. Neuroepidemiology 2015;44:149-155   

14. Dorst J, Dupuis L, Petri S, Kollewe K, Abdulla S, Wolf J, Weber M, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol 2015; 262:849-58   

15. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ. Factors predicting one-year mortality in amyotrophic lateral sclerosis patients - data from a population-based registry. BMC Neurology 2014;14:197  

16. Wolf J, Safer A, Wöhrle JC, Nix WA, Maschke M, Grau AJ. Variability and prognostic relevance of different phenotypes in amyotrophic lateral sclerosis - Data from a population-based registry. J Neurol Sci 2014;345:164-7   

17. Wolf J, Wöhrle JC, Palm F, Nix WA, Maschke M, Safer A, Becher H, Grau AJ. Incidence of amyotrophic lateral sclerosis in Rhineland-Palatinate, Germany. Amyotroph Lat Scler Frontotemp Degeneration 2014;15:269-74   

18. Palm F, Kraus M, Safer A, Wolf J, Chibuzor J, Becher H, Grau AJ. Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt). BMC Neurology 2014;14:199   

19. Urbanek C, Palm F, Buggle F, Wolf J, Safer A, Becher H, Grau AJ. Recent surgery or invasive procedures and the risk of stroke. Cerebrovasc Dis 2014;38:370-376   

20. Wolf J, Schmitt V, Palm F, Grau AJ, Bergner R. Peripheral neuropathy as initial manifestation of primary systemic vasculitides. J Neurol 2013;4:1061-70   

21. Palm F, Dos Santos M, Urbanek C, Greulich M, Zimmer K, Safer A, Grau AJ, Becher H. Stroke seasonality associations with subtype, etiology and laboratory results in the Ludwigshafen Stroke Study (LuSSt). Eur J Epidemiol 2013;28:373-81   

22. Palm F, Henschke N, Wolf J, Zimmer K, Safer A, Schröder RJ, Inselmann G, Brenk P,  Becher H, Grau AJ. Intracerebral hemorrhage in a population-based stroke registry (LuSSt) Incidence, aetiology, functional outcome and mortality. J Neurol 2013;260:2541-50   

23. Palm F, Kleemann T, Dos Santos M, Urbanek C, Buggle F, Safer A, Hennerici MG, Becher H, Zahn R, Grau AJ. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study). CHADS(2), CHA(2)DS(2)-VASc score, underuse of oral anticoagulation, and implications for preventive measures. Eur J Neurol 2013;20:117-23   

24. Palm F, Urbanek Ch, Wolf J, Buggle F, Kleemann T, Hennerici MG, Inselmann G, Hagar M, Safer A, Becher H, Grau AJ. Etiology, risk factors and sex-differences in ischemic stroke in the Ludwigshafen Stroke Study (LuSSt), a population-based stroke registry. Cerebrovasc Dis 2012;33:69-75   

25. Wolf J, Obermaier-Kusser B, Jacobs M, Milles C, Mörl M, Müller H, Grau AJ, Bauer MF. A new mitochondrial point mutation in the transfer RNA (Lysine) gene causing a clinical phenotype of progressive external ophthalmoplegia with impaired respiratory regulation. J Neurol Sci 2012;316:108-111   

26. Dos Santos M, Grond-Ginsbach C, Aksay SS, Chen B, Tchatchou S, Wolf NI, van der Knaap MS, Grau AJ. Adult-onset autosomal dominant leukodystrophy due to LMNB1 gene duplication. J Neurol 2012;259:579-81   

27. Tomaschütz L, Dos Santos M, Schill J, Palm F, Grau A. Recurrent amaurosis fugax in a patient after stanford type a dissection depending on blood pressure and haemoglobin level. Case Rep Vasc Med 2012;2012:254204   

28. Wolf J, Bergner R, Mutallib S, Buggle F, Grau AJ. Neurologic complications of Churg-Strauss syndrome.  Eur J Neurol 2010;17:582-588   

29. Wolf J, Maschke M, Nix WA, Wöhrle JC, Grau AJ. Amyotrophe Lateralsklerose-Register: Startschuss für ein landesweit einzigartiges Projekt. Neurotransmitter 2010;4:16-17   

30. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, Schielke E, Schmutzhard E, De Gans J, Chung CH, Luntz S, Hacke W, Meyding-Lamadé U, and GACHE Investigators (u.a. Wolf J). Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. BMC Neurol 2008;8:40   

31. Wolf J, Jacobi C, Breer H, Grau A. Das Chediak-Higashi-Syndrom. Nervenarzt 2006;77:148-157   

32. Wolf J. Schlaganfälle im jungen Erwachsenenalter. Neurotransmitter 2006;6:64-70   

33. Wolf J, Niedermaier N, Lowitzsch K. Schlaganfälle im jungen Erwachsenenalter. Nervenheilkunde 2005;24:681-5   

34. Sartorius A, Wolf J, Henn F. Lithium and ECT - concurrent use still demands attention. World J Biol Psychiatry 2005;6:313-17   

35. Wolf J, Sartorius A, Alm B, Henn F. Clozapine-induced lupus erythematosus. J Clin Psychopharmacol 2004;24:236-8   

36. Wolf J, Niedermaier N, Bergner R, Lowitzsch K. Zerebrale Vaskulitis als Erstmanifestation eines systemischen Lupus erythematodes. Dtsch Med Wschr 2001;126:947-50

1. Wolf J, Grau A. Metabolische Hirnstammerkrankungen in: Erkrankungen des Hirnstamms, Herausgeber: Urban P., Schattauer-Verlag 2008, 290-310   

2. Wolf J, Grau A. Metabolic Brainstem Diseases in: Brainstem Disorders, Editors: Urban P, Caplan LR, Springer-Verlag 2011, 303-326  

1. Hambsch N, Tews B, Niggemann P, Wolf J. Beta-Amyloid-assoziierte Angiitis (ABRA). 93. Kongress der Dt. Gesellschaft für Neurologie, 05.11.2020, Berlin

2. Gaudlitz M, Spittel S, Weyen U, Grehl T, Grosskreutz J, Steinbach R, Weydt P, Günther R, Wolf J, Baum P, Metelmann M, Koch JC, Kettemann D, Norden J, George A, Koc Y, Walter B, Münch C, Maier A, Meyer T. Therapeutische Bewegungsgeräte bei der ALS: Anwendungshäufigkeit und subjektiver Nutzen in einer multizentrischen Beobachtungsstudie. 93. Kongress der Dt. Gesellschaft für Neurologie, 05.11.2020, Berlin

3. Schischlevskij P, Cordts I, Günther R, Zeller D, Schröter C, Weyen U, Regensburger M, Wurster CD, Wolf J, Schneider I, Hermann A, Metelmann M, Kohl Z, Koch JC, Kastrati K, Osmanovic A, Klopstock T, Boentert M, Lulé DE, Hagenacker T, Lingor P, Petri S, Schreiber-Katz O. Belastung pflegender Angehöriger von Patienten mit amyotropher Lateralsklerose (ALS) und anderen Motoneuronerkrankungen in Deutschland, 93. Kongress der Dt. Gesellschaft für Neurologie, 05.11.2020, Berlin

4. Wolf J. Vaskulitische Neuropathien - Neues zu Diagnostik und Therapie. 92. Kongress der Dt. Gesellschaft für Neurologie, Stuttgart, 25.09.2019   

5. Witzel S, Hübers A, Michels S, Petri S, Lingor P, Koch C, Hermann A, Günther R, Wolf J, Weishaupt JH, Otto M, Ludolph AC. Therapie mit Edaravone bei der amyotrophen Lateralsklerose. Kongress des medizinisch-wissenschaftlichen Beirats der Dt. Gesellschaft für Muskelkranke, Göttingen, 10.05.2019   

6. Wolf J, Safer A, Wöhrle JC, Palm F, Nix WA, Maschke M, Grau AJ.  Causes of death in amyotrophic lateral sclerosis. Results from the Rhineland-Palatinate ALS registry. Kongress des European Network to Cure ALS (ENCALS), 20.06.2018, Oxford/Großbritannien   

7. Wolf J. Epidemiologie der Amyotrophen Lateralsklerose in Deutschland. Festvortrag zur Verleihung des Christa-Lorenz-ALS-Forschungspreises, 13.12.2017, Universitätsklinikum Magdeburg   

8. Funke A, Spittel S, Grehl T, Großkreutz J, Kettemann D, Petri S, Weyen U, Weydt P, Dorst J, Ludolph A, Baum P, Oberstadt M, Jordan B, Hermann A, Wolf J, Boentert M, Walter B, Gajewski N, Maier A, Münch C, Meyer T. Assistive technology devices in Amyotrophic Lateral Sclerosis - analysis of 4 years of platform-based case management. International Symposium on ALS/MND. 07.12.2017, Boston/USA.   

9. Bajwa A, Rittmann M, Behrang-Nia M, Martins Dos Santos M, Homenu W, Becker H, Dorner M, Lücke T, Wolf J. Wundbotulismus - eine wichtige Differentialdiagnose bei Drogenabhängigen. Jahrestagung der Deutschen Gesellschaft für Neurointensiv- und Notfallmedizin (ANIM). 17.02.2017, Wien   

10. Alkhasova N, Rittmann M, Wolf J. Adulte Manifestation einer Mitochondrienmembranprotein-assoziierten Neurodegeneration. Kongress der Deutschen Gesellschaft für Neurologie. 22.09.2016, Mannheim   

11. Sharifzadeh Tadi A, Rittmann M, Wolf J. Late onset-Variante einer Globoidzell-Leukodystrophie (Morbus Krabbe) - Fallbericht. Kongress der Deutschen Gesellschaft für Neurologie. 22.09.2016, Mannheim  (Posterpreis der DGN)   

12. Wolf J. Aktuelle diagnostische und therapeutische Optionen bei vaskulitischen Neuropathien. Kongress der Deutschen Gesellschaft für Neurologie. 22.09.2016, Mannheim   

13. Wolf J, Safer A, Wöhrle J, Palm F, Nix W, Maschke M, Grau A. Prognosefaktoren bei Erstdiagnose einer Amyotrophen Lateralsklerose. Kongress des Wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelkranke. 18.06.2015, Bochum   

14. Wolf J, Safer A, Wöhrle J, Palm F, Nix W, Maschke M, Grau A. Prognostische Bedeutung unterschiedlicher ALS-Phänotypen. Kongress der Deutschen Gesellschaft für Neurologie. 25.09.2015, Düsseldorf   

15. Safer A, Palm F, Nix W, Maschke M, Wöhrle J, Grau AJ, Wolf J. Prognosefaktoren für das Überleben bei amyotropher Lateralsklerose - Daten aus dem ALS-Register Rheinland-Pfalz. Jahrestagung der Dt. Gesellschaft für Epidemiologie. 18.09.2014, Ulm   

16. Wolf J, Wöhrle J, Palm F, Nix W, Maschke M, Becher H, Grau A. Incidence of amyotrophic lateral sclerosis in Rhineland-Palatinate, Germany. International Symposium on ALS/MND. 07.12.2013, Mailand/Italien   

17. Wolf J, Wöhrle J, Palm F, Nix W, Maschke M, Becher H, Grau A. Epidemiologie der amyotrophen Lateralsklerose in Deutschland - das ALS-Register Rheinland-Pfalz. Kongress der Deutschen Gesellschaft für Neurologie. 20.09.2013, Dresden

• Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, Stangel M, Fasshauer M, Gold R, Hensel M. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study. Eur J Haematol. 2017 Aug;99(2): 169-177.  
• Welz T, Wyen C, Hensel M. Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients. Oncol Res Treat. 2017;40(3):120-127. Review.
• Hentrich M, Hoffmann C, Mosthaf F, Müller M, Siehl J, Wyen C, Hensel M; German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ); German AIDS Society (DAIG). Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG). Ann Hematol. 2014 Jun;93(6):913-21. doi: 10.1007/s00277-014-2058-4. Epub 2014 Mar 29. Erratum in: Ann Hematol. 2014 Aug;93(8):1445.
• Hensel M, Brust J, Plöger C, Schuster D, Memmer ML, Franz-Werner J, Feustel HP, Karcher A, Fuxius S, Mosthaf FA, Rieger M, Ho AD, Witzens-Harig M.  Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol. 2012 Dec;91(12):1923-8.
• Hensel M, Goetzenich A, Lutz T, Stoehr A, Moll A, Rockstroh J, Hanhoff N, Jäger H, Mosthaf F. HIV and Cancer in Germany. Dtsch Arztebl Int. 2011 Feb;108(8):117-22. Epub 2011 Feb 25.
• Kornacker M, Kornacker B, Schmitt C, Leo E, Ho AD, Hensel M. Commercial LightCycler(R)-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma. Ann Hematol. 2009 Jan;88(1):43-50. Epub 2008 Jul 18.
• Hensel, M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer. 2009 Jan;17(1):47-52. Epub 2008 May 6.
• Schweizer C, Reu FJ, Ho AD, Hensel M. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.Ann Hematol. 2007 Oct;86(10):711-7. Epub 2007 Jul 11.
• Krämer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, Cross NC, Jones AV, Ho AD, Hensel M. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007 Jul;8(7):658-60. No abstract available.
• Hensel M, Dreger P, Ho AD. IgM-Gammopathie: Differentialdiagnose, Klinik und Therapie. Dtsch Arztebl 2007; 104(26): A-1907 / B-1684 / C-1620
• Hensel M, Zoz M, Giesecke C, Benner A, Neben K, Jauch A, Stilgenbauer S, Ho AD, Krämer A. High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. Int J Cancer. 2007 Sep 1;121(5):978-83.
• Ho AD, Hensel M. Pentostatin and purine analogs for indolent lymphoid malignancies. Future Oncol. 2006 Apr;2(2):169-83. Review.
• Ho AD, Hensel M. Pentostatin for the treatment of indolent lymphoproliferative disorders. Semin Hematol. 2006 Apr;43(2 Suppl 2):S2-10. Review.
• Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma. 2005 Sep;6(2):131-5.
• Hensel M, Buss EC, Tiemann M, Parwaresch R, Libicher M, Fruehauf S, Ho AD. Secondary follicular lymphoma of the bone, transformed into large cell lymphoma, in a patient with chronic lymphocytic leukaemia: an uncommon manifestation of Richter's syndrome. Eur J Haematol. 2004 Mar;72(3):217-21.
• Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia.
• Br J Haematol. 2003 Aug;122(4):600-6. PMID: 12899715 [PubMed - indexed for
• Hensel M, Ho AD. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. Am J Hematol. 2003 May;73(1):37-40.
• Hensel M, Ho AD, Bastert G, Schneeweiss A. Prognostic markers for survival after high-dose chemotherapy with autologous stem-cell transplantation for breast cancer. Ann Oncol. 2003 Feb;14(2):341. No abstract available.
• Hensel M, Fiehn C, Ho AD. [Stem cell transplantation in primary systemic vasculitis] Med Klin (Munich). 2003 Jan 15;98(1):13-8. Review. German.
• Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer. 2002 Jul 20;100(3):290-6.
• Hensel M, Egerer G, Schneeweiss A, Goldschmidt H, Ho AD. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol. 2002 Feb;13(2):209-17.
• Hensel M, Schneeweiss A, Sinn HP, Egerer G, Kornacker M, Solomayer E, Haas R, Bastert G, Ho AD. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support. Stem Cells. 2002;20(1):32-40.
• Schneeweiss A*, Hensel M*, Goerner R, Khbeis T, Hohaus S, Egerer G, Solomayer E, Haas R, Grischke EM, Bastert G, Ho AD. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. (*shared first author). Stem Cells. 2001;19(2):151-60.
• Hensel M, Breitbart A, Ho AD. Autologous hematopoietic stem-cell transplantation for Behçet's disease with pulmonary involvement. N Engl J Med. 2001 Jan 4;344(1):69. No abstract available

• Kriegsmann K, Rieger M, Schwarzbich MA, Sitter S, Kriegsmann M, Bruckner T, Hensel M, Ho AD, Witzens-Harig M, Wuchter P. Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol. 2018 Jul;101(1):12-20.
• Reiser M, Dörfel S, Hensel M, Hoesl M, Jordan WO, Koenigsmann M, Meyer D, Reichert D, Schwarzer A, Marquardt M, Kellershohn K, Jentsch-Ullrich K. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. Eur J Haematol. 2018 May;100(5):455-464.
• Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T. Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018 Jan 2;128(1)
• Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017 Feb;58(2):399-407.
• Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Reiser M, Sommer C. Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. Ther Adv Neurol Disord. 2016 May;9(3):165-79.
• Witzens-Harig M, Benner A, McClanahan F, Klemmer J, Brandt J, Brants E, Rieger M, Meissner J, Hensel M, Neben K, Dreger P, Lengfelder E, Schmidt-Wolf I, Krämer A, Ho AD. Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial. Br J Haematol. 2015 Dec;171(5):710-9.  
• Herth I, Hensel M, Rieger M, Horstmann K, Hiddemann W, Dreyling M, Koniczek S, Witzens-Harig M, Ho AD. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Leuk Lymphoma. 2015 Jan;56(1):97-102.
• Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C.  HIV-associated lung cancer: survival in an unselected cohort. Scand J Infect Dis. 2013 Oct;45(10):766-72.
• Fink AM, Böttcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, Wendtner CM, Winkler D, Bühler A, Zenz T, Staib P, Mayer J, Hensel M, Hopfinger G, Wenger M, Fingerle-Rowson G, Döhner H, Kneba M, Stilgenbauer S, Busch R, Hallek M. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.Leukemia. 2013 Sep;27(9):1949-52. Free PMC Article
• Martin Stangel, Ulrich Baumann, Michael Borte, Maria Fasshauer, Manfred Hensel, Dörte Huscher, Wilhelm Kirch, David Pittrow, Marcel Reiser, Ralf Gold. Treatment of Neurological Autoimmune Diseases With Immunoglobulins: First Insights From the Prospective SIGNS Registry. Martin Stangel, Ulrich Baumann, Michael Borte. J Clin Immunol. 2013 Jan;33 Suppl 1:S67-71.
• McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, Schmidt-Wolf I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, Leo E, Krämer A, Ho AD, Witzens-Harig.  Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. Am J Hematol. 2012 Jun 8. doi: 10.1002/ajh.23286. [Epub ahead of print]
• McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, Schmidt-Wolf I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, Leo E, Krämer A, Ho AD, Witzens-Harig M. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma. Am J Hematol. 2012 Jun 8. doi: 10.1002/ajh.23286. [Epub ahead of print] No abstract available.
• Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W, Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D, Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the GCLLSG CLL3 trial. Blood. 2012 Apr 5. [Epub ahead of print]
• Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, Reiser M, Stangel M, Gold R, Kirch W; Liste der aktuell beitragenden Zentren, sortiert nach Postleitzahlen (mindestens ein Patient zum 1.3.2012). [Immunoglobulins in PID, SID and neurological autoimmune disease]. Dtsch Med Wochenschr. 2012 Mar;137(13):675-80. Epub 2012 Mar 20. Review. German.
• Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K.Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.BMC Cancer. 2011 Feb 26;11:87.
• Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P.Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009 Apr;20(4):722-8. Epub 2009 Jan 29.
• Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.Lancet. 2010 Oct 2;376(9747):1164-74.
• Kirch W, Gold R, Hensel M, Fasshauer M, Pittrow D, Huscher D, Reiser M, Stangel M, Baumann U, Borte M. Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods. Med Klin (Munich). 2010 Sep;105(9):647-51. Epub 2010 Sep 28. German.
• Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S. TP53 mutation and survival in chronic lymphocytic leukemia.J Clin Oncol. 2010 Oct 10;28(29):4473-9. Epub 2010 Aug 9.
• McClanahan F, Hielscher T, Rieger M, Hensel M, Neben K, Hillengass J, Herfarth K, Ho AD, Witzens-Harig M. Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy.Eur J Haematol. 2010 Jul;85(1):11-9. Epub 2010 Mar 16.
• Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group.Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.J Clin Oncol. 2009 Aug 20;27(24):3994-4001. Epub 2009 Jul 13.
• Kornacker M, Stumm J, Pott C, Dietrich S, Süssmilch S, Hensel M, Nickelsen M, Witzens-Harig M, Kneba M, Schmitz N, Ho AD, Dreger P. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up.Ann Oncol. 2009 Apr;20(4):722-8. Epub 2009 Jan 29.
• Witzens-Harig M, Reiz M, Heiß C, Benner A, Hensel M, Neben K, Dreger P, Kraemer A, Ho AD. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial. Ann Hematol. 2009 Jan;88(1):51-7. Epub 2008 Jul 30.
• Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL).Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).Ann Hematol. 2008 Sep;87(9):717-26. Epub 2008 Jun 28.
• Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, Fritz B, Schwarz A, Suri-Payer E, Hensel M, Wildemann B. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis.Blood. 2008 Jan 15;111(2):761-6. Epub 2007 Oct 29.
• Dreger P, Rieger M, Seyfarth B, Hensel M, Kneba M, Ho AD, Schmitz N, Pott C. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica. 2007 Jan;92(1):42-9.
• Witzens-Harig M, Heilmann C, Hensel M, Kornacker M, Benner A, Haas R, Fruehauf S, Ho AD. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.Stem Cells. 2007 Jan;25(1):228-35.
• Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlueter M, Hensel M, Flieger D, Glasmacher AG, Schmidt-Wolf IG. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006 Dec;47(12):2558-66.
• Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.Cancer Invest. 2006 Oct;24(6):593-600.
• Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F, Gotze K, Nerl C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Matzdorff A, Salwender H, Biedermann HG, Kremers S, Haase D, Benner A, Dohner K, Dohner H. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial. Leukemia. 2006 Apr;20(4):748-50.
• Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma.Int J Cancer. 2006 Sep 15;119(6):1377-82.
• Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jaeger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Doehner H, Brittinger G, Emmerich B, Hallek M. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia.Blood. 2006 Feb 1;107(3):885-91. Epub 2005 Oct 11.
• Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, Leo E. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?Leuk Res. 2006 Dec;30(12):1563-8. Epub 2006 Mar 10.
• Schmitt C, Balogh B, Grundt A, Buchholtz C, Leo A, Benner A, Hensel M, Ho AD, Leo E. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity.Leuk Res. 2006 Jun;30(6):745-50. Epub 2005 Nov 16.
• Maurer B, Hensel M, Max R, Fiehn C, Ho AD, Lorenz HM. Autologous haematopoietic stem cell transplantation for Behcet's disease with pulmonary involvement: analysis after 5 years of follow up.Ann Rheum Dis. 2006 Jan;65(1):127-9. Epub 2005 May 26.
• Nikendei C, Schilling T, Nawroth P, Hensel M, Ho AD, Schwenger V, Zeier M, Herzog W, Schellberg D, Katus HA, Dengler T, Stremmel W, Müller M, Jünger J. [Integrated skills laboratory concept for undergraduate training in internal medicine]. Dtsch Med Wochenschr. 2005 May 6;130(18):1133-8. German.
• Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, Del Valle Y Fuentes F, Gotze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L, Dohner K, Frohling S, Dohner H. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 2005 Jun;19(6):978-83.
• Bochtler T, Hensel M, Lorenz HM, Ho AD, Mahlknecht U. Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases.Rheumatology (Oxford). 2005 Sep;44(9):1199. Epub 2005 Apr 26.
• Schneeweiss A, Diel I, Hensel M, Kaul S, Sinn HP, Unnebrink K, Rudlowski C, Lauschner I, Schuetz F, Egerer G, Haas R, Ho AD, Bastert G. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.Ann Oncol. 2004 Nov;15(11):1627-32.
• Reusch U, Le Gall F, Hensel M, Moldenhauer G, Ho AD, Little M, Kipriyanov SM. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.Int J Cancer. 2004 Nov 10;112(3):509-18.
• Mechtersheimer G, Egerer G, Hensel M, Rieker RJ, Libicher M, Lehnert T, Penzel R. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch. 2004 Feb;444(2):108-18. Epub 2004 Jan 20. Review.
• Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group.
• Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.J Clin Oncol. 2003 Jul 15;21(14):2747-53.
• Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Frohling S, Dohner K, Haas R, Dohner H; AML Study Group Ulm (AMLSG ULM). Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003 Aug;17(8):1521-8.
• Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J, Kröger N, Hensel M, Scheffold C, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W. Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.Ann Hematol. 2002;81 Suppl 2:S47-8.
• Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group. Phase-II Study of a combined Immuno-Chemotherapy using Rituximab and Fludarabine in Patients With Chronic Lymphocytic Leukemia Blood 2002 Nov 1;100(9):3115-20
• Egerer G, Goldschmidt H, Hensel M, Harter C, Schneeweiss A, Ehrhard I, Bastert G, Ho AD. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.Bone Marrow Transplant. 2002 Oct;30(7):427-31.
• Schneeweiss A, Hensel M, Sinn P, Khbeis T, Haas R, Bastert G, Ho AD. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.Ann Oncol. 2002 May;13(5):679-88.
• Egerer G, Hensel M, Ho AD. Infectious complications in chronic lymphoid malignancy.Curr Treat Options Oncol. 2001 Jun;2(3):237-44. Review.
• Schlenk RF, Hartmann F, Hensel M, Jung W, Weber-Nordt R, Gabler A, Haas R, Ho AD, Trümper L, Döhner H. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.Leukemia. 2002 Apr;16(4):581-6.
• Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.Leuk Lymphoma. 2002 Jan;43(1):149-51.
• Schneeweiss A, Goerner R, Hensel M, Lauschner I, Sinn P, Kaul S, Egerer G, Beldermann F, Geberth M, Solomayer E, Grischke EM, Haas R, Ho AD, Bastert G. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.Biol Blood Marrow Transplant. 2001;7(6):332-42.

• Hensel M., Witzens-Harig M.: Niedrigmaligene Non-Hodgkin-Lymphome beim alten und geriatrischen Patienten. In: Geriatrische Onkologie. Hrsg.: Ebert, Härtel, Wedding. Springer Verlag 2018
• Hensel M.: Multiple Myeloma and Monoclonal Gammopathy of Unknown Significance. In: HIV-associated Hematological Malignancies. Hrsg.: Hentrich, Barta. Springer Verlag 2017
• Hensel M. Chemotherapeutika und Anästhesie. In: Anästhesie in der Traumatologie und Orthopädie. Hrsg.: Th. Frietsch, A. Weiler-Lorentz. Urban&Fischer Verlag, München 2009
• Hinkelbein J, Feller-Heppt G, Lenz C, Hensel M, Frietsch T. Mastozytose: Pathologie und anästhesiologische Implikationen für die Praxis. 2008
• Hensel M. Einsatz monoklonaler Antikörper bei malignen Lymphomen (Rituximab, Zevalin/Bexxar, Epratuzumab, HuMax-CD20, Galiximab). In: Antikörpertherapie in der Hämatologie und Onkologie. UNI-MED Verlag Bremen. 2007
• Hensel M. Substitution von Immunglobulinen. In: Supportivtherapie bei malignen Erkrankungen. Herausgeber: Link; Bokemeyer, Feyer. Deutscher Ärzteverlag Köln, 2006
• Fiehn C, Hensel M. High Dose Chemotherapy with Haematopoietic Stem Cell Transplantation in Primary Systemic Vasculitis, Behcet`s disease and Sjoegren`s Syndrome. Stem Cell Therapy for Autoimmune Disease. eds. Marmont and Burt; Landes Bioscience, Georgetown, USA. 2003